Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Metered-dose inhaler Stories

2011-05-24 05:03:00

CAMBRIDGE, Mass. and ST. PAUL, Minn., May 24, 2011 /PRNewswire/ -- Radius Health, Inc. ("Radius") and 3M Drug Delivery Systems ("3M") today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis. The BA058 Microneedle Patch will use 3M's patented Microstructured Transdermal System microneedle technology to administer BA058 through the...

2011-05-18 09:15:00

REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented detailed efficacy and safety results today from the Company's phase 2b study of PT003 (GFF MDI) in patients with moderate-to-very severe COPD during a late-breaker poster session at the annual meeting of the American Thoracic Society (ATS). PT003 is a proprietary fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (FF), an established,...

16f6f3708d76ec7c8a74e51fe5ef48bf
2011-05-13 07:57:28

Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal. This study is the first to assess the effectiveness of using a nicotine-free inhaler to help stop smoking. The research, which was carried out by scientists at the Università di Catania in Italy, analyzed 120 people who were enrolled in a program to help them quit smoking. The participants were split into two groups, with...

2011-05-05 08:00:00

REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. made three presentations at the Respiratory Drug Delivery Europe (RDD Europe 2011) meeting in Berlin this week elucidating the tunability, versatility and universality of the Company's porous particle-based metered dose inhaler (MDI) development approach. The data provides details of Pearl's products and novel cosuspension platform, which facilitates forming stable MDI suspensions containing respiratory drugs as...

2011-04-29 08:00:00

REDWOOD CITY, Calif., April 29, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society (ATS). PT003 (GFF-MDI) is a proprietary, fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, an established, long-acting...

2011-04-01 08:21:30

By Helena Pujol, Ivanhoe Health Correspondent (Ivanhoe Newswire) "“  A new treatment is helping sufferers of  Chronic Obstructive Pulmonary Disease (COPD) find relief in the form of a hand-held device to inhaled medication. The SPIRIVA HandiHaler is the first once-daily steroid free treatment that reduces the worsening of symptoms (exacerbations) in people with COPD, and can help manage the disease long term. "In the United States, 12 million people have been diagnosed with...

2011-03-01 10:00:00

CHICAGO, March 1, 2011 /PRNewswire/ -- Developed by inventor John Vito and represented by ICAP Ocean Tomo, the assets available for auction in this lot disclose an advanced medical inhaler design that is both more accurate and more convenient for the user. (Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO) The patents will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. Key Characteristics The patents disclose the...

2011-02-09 08:00:00

MIDLOTHIAN, Va., Feb. 9, 2011 /PRNewswire/ -- Today, PARI Respiratory Equipment launched an updated company website at www.pari.com. In addition to providing visitors with a beautiful new interface, the website includes easy access to: Continuing Education classes Product instructional videos Frequently asked questions and answers for patients Product instructions for use Information on how to access and differentiate between various types of nebulizers, compressors, holding chambers,...

2010-12-01 07:00:00

REDWOOD CITY, Calif., Dec. 1, 2010 /PRNewswire/ -- Pearl Therapeutics Inc. today announced that their lead combination bronchodilator, PT003, met the primary efficacy endpoint in a recently completed Phase 2b clinical trial in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). These top-line results show that PT003 provides superior bronchodilation compared to the current market leader, tiotropium bromide (Spiriva®...

2010-10-19 08:00:00

REDWOOD CITY, Calif., Oct. 19 /PRNewswire/ -- Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures. With this...


Latest Metered-dose inhaler Reference Libraries

Nicotine Replacement Therapy
2013-03-04 16:06:28

Nicotine replacement therapy is the administration of nicotine by other means than smoking. This change in the way nicotine is delivered prevents the harmful effects of smoking and is usually used in smoking cessation. Types Nicotine replacement therapy can be administered in several forms. The type used depends on the patient and what fits into their lifestyle best. The forms available include: Nicotine patches – transdermal (through the skin) Nicotine gum – orally (through the...

More Articles (1 articles) »